vs
Side-by-side financial comparison of Protalix BioTherapeutics, Inc. (PLX) and TECHPRECISION CORP (TPCS). Click either name above to swap in a different company.
Protalix BioTherapeutics, Inc. is the larger business by last-quarter revenue ($9.1M vs $7.1M, roughly 1.3× TECHPRECISION CORP). TECHPRECISION CORP runs the higher net margin — -20.8% vs -60.3%, a 39.6% gap on every dollar of revenue. On growth, TECHPRECISION CORP posted the faster year-over-year revenue change (-6.9% vs -49.9%). Protalix BioTherapeutics, Inc. produced more free cash flow last quarter ($1.6M vs $-827.0K). Over the past eight quarters, Protalix BioTherapeutics, Inc.'s revenue compounded faster (-6.7% CAGR vs -9.2%).
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
TechPrecision Corp is a manufacturer of custom high-precision metal fabricated components and integrated systems, serving aerospace, defense, medical technology, renewable energy, and industrial end markets primarily across North America and Europe. It specializes in producing tight-tolerance, mission-critical parts that adhere to rigorous industry quality requirements.
PLX vs TPCS — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $9.1M | $7.1M |
| Net Profit | $-5.5M | $-1.5M |
| Gross Margin | 49.4% | 5.4% |
| Operating Margin | -51.1% | -19.1% |
| Net Margin | -60.3% | -20.8% |
| Revenue YoY | -49.9% | -6.9% |
| Net Profit YoY | -184.8% | -84.4% |
| EPS (diluted) | $-0.06 | $-0.15 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.1M | $7.1M | ||
| Q3 25 | $17.9M | $9.1M | ||
| Q2 25 | $15.7M | $7.4M | ||
| Q1 25 | $10.1M | $9.5M | ||
| Q4 24 | $18.2M | $7.6M | ||
| Q3 24 | $18.0M | $8.9M | ||
| Q2 24 | $13.5M | $8.0M | ||
| Q1 24 | — | $8.6M |
| Q4 25 | $-5.5M | $-1.5M | ||
| Q3 25 | $2.4M | $825.0K | ||
| Q2 25 | $164.0K | $-597.0K | ||
| Q1 25 | $-3.6M | $112.0K | ||
| Q4 24 | $6.5M | $-799.0K | ||
| Q3 24 | $3.2M | $-601.0K | ||
| Q2 24 | $-2.2M | $-1.5M | ||
| Q1 24 | — | $-5.1M |
| Q4 25 | 49.4% | 5.4% | ||
| Q3 25 | 53.4% | 27.1% | ||
| Q2 25 | 62.5% | 14.0% | ||
| Q1 25 | 19.1% | 22.0% | ||
| Q4 24 | 78.7% | 13.0% | ||
| Q3 24 | 53.4% | 11.3% | ||
| Q2 24 | 29.8% | 3.0% | ||
| Q1 24 | — | 14.3% |
| Q4 25 | -51.1% | -19.1% | ||
| Q3 25 | 11.9% | 10.4% | ||
| Q2 25 | 7.5% | -6.3% | ||
| Q1 25 | -41.0% | 3.9% | ||
| Q4 24 | 39.6% | -9.1% | ||
| Q3 24 | 22.2% | -5.5% | ||
| Q2 24 | -18.0% | -16.8% | ||
| Q1 24 | — | -28.6% |
| Q4 25 | -60.3% | -20.8% | ||
| Q3 25 | 13.2% | 9.1% | ||
| Q2 25 | 1.0% | -8.1% | ||
| Q1 25 | -35.8% | 1.2% | ||
| Q4 24 | 35.6% | -10.5% | ||
| Q3 24 | 18.0% | -6.7% | ||
| Q2 24 | -16.4% | -18.3% | ||
| Q1 24 | — | -59.5% |
| Q4 25 | $-0.06 | $-0.15 | ||
| Q3 25 | $0.03 | $0.08 | ||
| Q2 25 | $0.00 | $-0.06 | ||
| Q1 25 | $-0.05 | $0.01 | ||
| Q4 24 | $0.10 | $-0.08 | ||
| Q3 24 | $0.03 | $-0.06 | ||
| Q2 24 | $-0.03 | $-0.16 | ||
| Q1 24 | — | $-0.59 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $14.7M | $50.0K |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $48.2M | $8.0M |
| Total Assets | $82.3M | $32.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $14.7M | $50.0K | ||
| Q3 25 | $13.6M | $220.0K | ||
| Q2 25 | $17.9M | $143.0K | ||
| Q1 25 | $19.5M | $195.0K | ||
| Q4 24 | $19.8M | $165.0K | ||
| Q3 24 | $27.4M | $132.0K | ||
| Q2 24 | $23.4M | $44.8K | ||
| Q1 24 | — | $138.0K |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $3.0K | ||
| Q4 24 | — | $19.0K | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $48.2M | $8.0M | ||
| Q3 25 | $52.9M | $9.1M | ||
| Q2 25 | $49.9M | $8.2M | ||
| Q1 25 | $45.2M | $8.7M | ||
| Q4 24 | $43.2M | $8.1M | ||
| Q3 24 | $32.4M | $8.9M | ||
| Q2 24 | $28.6M | $7.9M | ||
| Q1 24 | — | $7.8M |
| Q4 25 | $82.3M | $32.8M | ||
| Q3 25 | $82.3M | $33.8M | ||
| Q2 25 | $78.5M | $32.1M | ||
| Q1 25 | $73.9M | $33.5M | ||
| Q4 24 | $73.4M | $32.2M | ||
| Q3 24 | $61.6M | $35.0M | ||
| Q2 24 | $91.5M | $35.7M | ||
| Q1 24 | — | $34.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 0.00× | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $2.0M | $183.0K |
| Free Cash FlowOCF − Capex | $1.6M | $-827.0K |
| FCF MarginFCF / Revenue | 17.8% | -11.7% |
| Capex IntensityCapex / Revenue | 4.4% | 14.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-13.6M | $-4.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.0M | $183.0K | ||
| Q3 25 | $-3.7M | $-1.1M | ||
| Q2 25 | $-5.2M | $646.0K | ||
| Q1 25 | $-5.1M | $396.0K | ||
| Q4 24 | $4.0M | $-570.0K | ||
| Q3 24 | $4.1M | $-532.0K | ||
| Q2 24 | $-3.6M | $107.0K | ||
| Q1 24 | — | $-452.0K |
| Q4 25 | $1.6M | $-827.0K | ||
| Q3 25 | $-4.2M | $-2.1M | ||
| Q2 25 | $-5.7M | $-604.0K | ||
| Q1 25 | $-5.4M | $-930.0K | ||
| Q4 24 | $3.6M | $-1.7M | ||
| Q3 24 | $4.0M | $-2.0M | ||
| Q2 24 | $-3.8M | $-94.0K | ||
| Q1 24 | — | $-900.0K |
| Q4 25 | 17.8% | -11.7% | ||
| Q3 25 | -23.7% | -22.9% | ||
| Q2 25 | -36.2% | -8.2% | ||
| Q1 25 | -53.0% | -9.8% | ||
| Q4 24 | 19.6% | -22.9% | ||
| Q3 24 | 22.4% | -21.8% | ||
| Q2 24 | -28.1% | -1.2% | ||
| Q1 24 | — | -10.5% |
| Q4 25 | 4.4% | 14.2% | ||
| Q3 25 | 2.8% | 11.0% | ||
| Q2 25 | 2.8% | 16.9% | ||
| Q1 25 | 3.0% | 14.0% | ||
| Q4 24 | 2.3% | 15.4% | ||
| Q3 24 | 0.5% | 15.9% | ||
| Q2 24 | 1.3% | 2.5% | ||
| Q1 24 | — | 5.2% |
| Q4 25 | — | — | ||
| Q3 25 | -1.58× | -1.31× | ||
| Q2 25 | -31.91× | — | ||
| Q1 25 | — | 3.54× | ||
| Q4 24 | 0.61× | — | ||
| Q3 24 | 1.27× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
TPCS
| Defense | $6.7M | 94% |
| Other | $410.0K | 6% |
